Standard Implementation vs Intensive Implementation: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0914 | 0.0839 | 0.0995 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0727 | 0.0682 | 0.0776 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0187 | 0.00975 | 0.0279 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.26 | 1.13 | 1.4 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.28 | 1.14 | 1.44 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on Standard Implementation than on Intensive Implementation | 53.6 | 35.8 | 103 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Standard Implementation | Promotion, Tool Access, academic detailing + Audit and Feedback~Promotion, and Tool Access: All sites will be given access to a You Tube video that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.~Audit and Feedback: Sites will be provided with reports to provide feedback on the screening and shared decision making process. Site teams were encouraged to send these reports to providers.~Academic Detailing: All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations. | 482 | 5,275 | EG000 | ClinicalTrials.gov |
| Group 2 | Intensive Implementation | Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP~Promotion, and Tool Access: All sites will be given access to a You Tube video that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.~LEAP: Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).~Audit and Feedback: Sites will be provided with reports to provide feedback on the screening and shared decision making process. Site teams were encouraged to send these reports to providers.~Academic Detailing: All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations. | 855 | 11,758 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | PrOVE QUERI Project #1 | ClinicalTrials.gov |
| NCT number | NCT02765412 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Prevention and Control | ClinicalTrials.gov |
| Interventions | Webinar, Promotion, and Tool Access, LEAP, Audit and Feedback, Academic Detailing | ClinicalTrials.gov |
| Lead sponsor | VA Office of Research and Development | ClinicalTrials.gov |
| Results first posted | 2024-12-31 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02765412?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.